The brand drug lobby says congressional efforts to make pharmacy benefit managers’ rebate practices more transparent are a good first step, but PBMs are now shifting to a new business model where opaque fees and specialty pharmacy markups comprise a greater share of their profits. The Pharmaceutical Research and Manufacturers of America released a new study Monday (Sept. 18) laying out the new PBM model, and today said Congress needs to beef up pending PBM reform bills in testimony before...